A research team has made a breakthrough in epigenetic drug discovery. The researchers have successfully developed a first-in-class chemical inhibitor that precisely and selectively targets the ATAC complex, a critical cellular "switch operator" that activates tumor-promoting genes, opening a novel therapeutic avenue for non-small cell lung cancer (NSCLC).
from Medical Xpress - latest medical and health news stories https://ift.tt/lc5GSmk
